United States Patent 5,859,186: Scope, Claim Construction, Expiration and Ziconotide Patent Landscape

US 5,859,186 covers methods of producing analgesia with omega conopeptides that show pharmacologic activity at the omega-conotoxin MVIIA binding site and inhibit electrically stimulated contraction of guinea pig ileum. The patent specifically identifies MVIIA, also known as SNX-111 and ziconotide, and related peptides including TVIA/SNX-185, SNX-199, SNX-236 and SNX-239.

The patent issued on January 12, 1999, from an application filed in January 1996, with an earlier January 1995 priority claim. Its nominal United States patent term ended in January 2016. The patent is therefore expired and does not currently block manufacture, sale or use of ziconotide or other compounds falling within its former claims.

What does US Patent 5,859,186 protect?

US 5,859,186 protects a therapeutic method, not the chemical composition of every omega conopeptide. Its principal claim requires four elements:

Administration to a mammalian subject.
Production of analgesia.
Use of an omega conopeptide.
Demonstration of two specified pharmacologic properties:
- inhibition of electrically stimulated guinea pig ileum contraction; and
- selective binding to neuronal omega-conopeptide MVIIA binding sites.

The claim is functional. It does not require a particular dose, route of administration, formulation, disease diagnosis or commercial product. A peptide falls within claim 1 only if it satisfies the claimed pharmacologic activity ranges.

Patent identification and prosecution data

Item	Data
Patent	US 5,859,186
Title	Methods of producing analgesia using omega conopeptides
Filing date	January 1996
Priority date	January 1995
Issue date	January 12, 1999
Original assignee	Neurex Corporation
Principal technology	Omega-conotoxin analgesics
Lead compound	MVIIA, SNX-111, ziconotide
Nominal expiration	January 2016
Current status	Expired
Therapeutic use	Analgesia, including chronic and neuropathic pain

The patent is part of the early Neurex omega-conotoxin portfolio that preceded commercial development of ziconotide. The claims are directed to biological activity and use rather than only to a defined amino-acid sequence. That drafting approach gave the patent broader theoretical coverage than a claim limited to synthetic MVIIA.

How broad is claim 1 of US 5,859,186?

Claim 1 is broad in subject matter but constrained by assay results. It does not merely cover any conopeptide administered for pain. The peptide must satisfy both the guinea pig ileum inhibition test and the MVIIA-site binding test.

Functional limitation: guinea pig ileum assay

The guinea pig ileum assay measures inhibition of electrically stimulated smooth-muscle contraction. Omega-conotoxins that block voltage-gated calcium channels can suppress neurotransmitter release and reduce electrically induced contraction.

The claim requires activity within the ranges associated with MVIIA and TVIA. The specification and associated experimental data are therefore important to determining the boundaries of the claim. The words "within the ranges" incorporate a comparative biological standard rather than a fixed chemical structure.

This limitation creates two consequences:

A structurally different peptide could potentially fall within the claim if it produces the required assay profile.
A peptide structurally related to MVIIA might fall outside the claim if its activity is materially weaker, stronger in a non-overlapping range, or directed to a different channel subtype.

Functional limitation: MVIIA binding-site selectivity

The second required activity is selective binding to omega-conopeptide MVIIA binding sites in neuronal tissue. This limitation distinguishes the claimed compounds from conopeptides directed primarily at other omega-conotoxin binding sites.

The claim does not define selectivity by a single universal numerical threshold. Instead, it refers to the activity ranges of MVIIA and TVIA. Claim construction would therefore depend heavily on:

the assay used;
the tissue source;
the radioligand or tracer;
the comparator peptide;
the concentration range;
the definition of specific versus nonspecific binding; and
the numerical ranges disclosed in the specification.

The claim is consequently stronger against a clearly MVIIA-like peptide than against a distant conopeptide whose binding profile requires a disputed assay interpretation.

What does claim 2 add?

Claim 2 narrows claim 1 through a selectivity ratio comparing binding at the MVIIA site with binding at a site 2 omega-conopeptide binding site.

The specified comparator group includes:

MVIIA/SNX-111;
SNX-199;
SNX-236;
SNX-239; and
TVIA/SNX-185.

This limitation is important because it focuses on receptor or binding-site discrimination rather than absolute affinity alone. A candidate peptide with strong binding to the MVIIA site but similarly strong binding to site 2 could fail the claim 2 ratio limitation.

Claim 2 is narrower than claim 1 because it requires an additional comparative pharmacology result. It also creates evidentiary issues in litigation. The parties would likely dispute the appropriate site 2 assay, the calculation of the ratio, and whether the claimed range must be measured under the same conditions used for the named reference peptides.

Which sequences are expressly identified in claim 3?

Claim 3 identifies a closed group of named peptide sequences and their derivatives.

SEQ ID	Designation
SEQ ID NO: 7	TVIA/SNX-185
SEQ ID NO: 1	MVIIA/SNX-111
SEQ ID NO: 30	SNX-236
SEQ ID NO: 2	SNX-159
SEQ ID NO: 32	SNX-239
SEQ ID NO: 33	SNX-199

Claim 3 is materially more specific than claim 1. It requires selection from the identified sequence group, subject to the phrase "and derivatives thereof."

What are the likely boundaries of "derivatives thereof"?

The term "derivatives" may encompass modified versions of the listed peptides, depending on the specification's disclosure and the ordinary meaning established during prosecution. Potential categories include:

conservative amino-acid substitutions;
terminal modifications;
disulfide-bond variants;
non-natural amino-acid substitutions;
labeled derivatives;
amidated or otherwise chemically modified termini; and
analogues retaining the claimed analgesic activity.

The term does not automatically cover every peptide with similar pharmacology. A derivative must remain connected to the claimed parent sequence and must also satisfy the limitations inherited from claim 1.

A product claim to a specific derivative would require separate analysis of written description, enablement and prosecution history. The scope is not equivalent to a blanket claim over all calcium-channel-blocking peptides.

What do claims 4 and 5 cover?

Claim 4 limits the treatment to a subject experiencing chronic pain. Claim 5 further limits chronic pain to neuropathic pain.

The dependent-claim structure is:

Claim 1: analgesia using a pharmacologically defined omega conopeptide.
Claim 4: claim 1 applied to chronic pain.
Claim 5: claim 4 applied to neuropathic pain.

These claims are method-of-use claims. They do not independently claim:

a composition;
a vial;
an intrathecal pump;
a formulation;
a dosing regimen;
a manufacturing process; or
a device.

The claims are compatible with intrathecal administration, which became central to commercial ziconotide use, but the provided claim language does not expressly require the intrathecal route.

How does the patent relate to ziconotide and Prialt?

Ziconotide is synthetic omega-conopeptide MVIIA, also known as SNX-111. It is a selective N-type voltage-gated calcium-channel blocker. The FDA approved Prialt, the commercial ziconotide product, in December 2004 for severe chronic pain requiring intrathecal therapy, including patients intolerant of or refractory to other treatments (FDA, 2023).

US 5,859,186 is directly relevant to ziconotide because:

claim 3 expressly names MVIIA/SNX-111;
claims 1 and 2 describe the pharmacologic activity associated with MVIIA;
claims 4 and 5 cover chronic and neuropathic pain; and
the commercial indication is a chronic-pain use.

The patent was an important early method-of-use asset, but its expiration occurred before the modern commercial patent life of Prialt became the principal regulatory issue.

What is the Orange Book status of US 5,859,186?

The patent was associated with the Prialt regulatory record and was historically relevant to Orange Book exclusivity analysis. Its patent term ended in January 2016, so it is no longer an enforceable Orange Book barrier.

FDA approval of Prialt does not create continuing patent protection. The product's regulatory approval, any remaining regulatory exclusivity, and patent rights are separate legal mechanisms.

Regulatory issue	Assessment
NDA	Prialt NDA 021060
Active ingredient	Ziconotide acetate
Dosage form	Intrathecal infusion solution
Original approval	December 2004
NCE exclusivity	Five-year period associated with original approval
US 5,859,186	Expired
Current blocking effect	None from this patent
Biosimilar pathway	Not applicable to this synthetic peptide product
Generic pathway	Potentially relevant through an ANDA or other abbreviated route, subject to FDA classification and product complexity

The five-year new chemical entity exclusivity period associated with the original approval would have ended years before the patent expiration. No current commercial exclusivity can be based on that historical period.

When did US 5,859,186 lose exclusivity?

The patent lost enforceable patent protection in January 2016, based on the standard 20-year term measured from the relevant nonprovisional filing date, subject to any adjustment or extension. No patent term extension is generally associated with US 5,859,186.

Its expiration has three commercial consequences:

A manufacturer no longer needs a license to practice the expired patent claims.
A Paragraph IV challenge directed only to this patent no longer creates a meaningful launch risk.
Freedom to operate still requires review of later-expiring patents, regulatory requirements and manufacturing know-how.

The expiration does not invalidate other patents in the ziconotide portfolio. It removes only the rights conferred by this patent.

What patent landscape surrounds ziconotide?

The ziconotide landscape has historically included several distinct patent categories.

Composition and sequence patents

These patents cover MVIIA, related omega-conopeptides, analogues and derivatives. Composition claims are generally stronger than broad functional method claims because infringement can be established from the structure of the accused peptide rather than from a disputed in vitro assay.

Method-of-use patents

US 5,859,186 is principally a method-of-use patent. Other use patents in the field have addressed:

treatment of chronic pain;
neuropathic pain;
intrathecal administration;
dosing and titration;
reduction of adverse effects; and
use in patients refractory to opioids or other analgesics.

A current freedom-to-operate review must separate expired foundational claims from later patents that may cover a dosing protocol or patient population.

Formulation patents

Ziconotide is a peptide administered directly into the cerebrospinal fluid. Formulation and storage issues can create separate patent positions involving:

concentration ranges;
pH and buffer systems;
preservatives;
container compatibility;
stability;
infusion reservoirs; and
admixtures with other intrathecal agents.

US 5,859,186 does not claim these formulation features. A manufacturer could avoid its expired method claims while still needing to evaluate later formulation or device patents.

Manufacturing and process patents

Manufacturing barriers may involve:

solid-phase peptide synthesis;
oxidative folding;
disulfide-bond pairing;
purification;
impurity control;
endotoxin reduction; and
release specifications.

For ziconotide, manufacturing expertise can be a more significant practical barrier than the expired analgesia patent. Process patents must be reviewed independently from product and method patents.

Delivery-system and device patents

Prialt is delivered by an approved intrathecal infusion system. Pump compatibility, reservoir materials, programming and administration methods may be protected by device or combination-product patents. These rights are separate from the peptide patent and may affect commercial launch strategy.

Are there biosimilar risks for ziconotide?

Traditional biosimilar risk is limited because ziconotide is a synthetic peptide rather than a reference biologic regulated through the principal biosimilar framework.

The competitive risk is more likely to involve a generic or follow-on synthetic peptide product. FDA approval would require adequate demonstration of pharmaceutical quality, identity, potency, purity, sterility and clinical or bridging comparability appropriate to the regulatory pathway.

The principal technical challenges are:

correct disulfide connectivity;
peptide-related impurities;
aggregation and degradation;
sterility for intrathecal administration;
potency assay reproducibility;
container and pump compatibility; and
clinical risk management for severe neurologic adverse reactions.

An abbreviated regulatory pathway does not eliminate the need to address manufacturing and clinical comparability.

Which companies are challenging the Prialt patent estate?

US 5,859,186 no longer presents a live Paragraph IV target because it expired in 2016. A company seeking to enter the ziconotide market would instead examine any later-expiring patents listed for the product, regulatory exclusivity, FDA product-specific requirements and manufacturing patents.

The relevant competitive groups are:

Competitor type	Principal risk
Generic peptide manufacturer	Product quality, sterility and equivalence
Specialty injectable company	Intrathecal delivery and hospital access
Peptide contract manufacturer	Process capability and supply reliability
Drug-device developer	Pump compatibility and administration system
Pain-therapy company	Substitution by non-ziconotide intrathecal or systemic products

No biosimilar interchangeability analysis applies in the ordinary monoclonal-antibody sense.

How strong was the patent estate?

The estate was strongest during the period when three conditions overlapped:

ziconotide had a differentiated pharmacologic mechanism;
the patent specifically named MVIIA and related active peptides; and
FDA-approved intrathecal use created a commercial product linked to the claimed pain indications.

Its weaknesses were equally specific:

claim 1 depended on biological assay ranges;
claim 2 depended on comparative binding ratios;
the patent did not claim every formulation or device used with ziconotide;
the patent did not provide permanent protection for the molecule; and
the entire patent expired in January 2016.

The practical strength of the estate therefore shifted over time from patent exclusion to regulatory, manufacturing and commercialization barriers.

What generic launch scenarios exist after expiration?

A post-expiration entrant could pursue several strategies:

Develop a synthetic ziconotide product with the same active sequence.
Seek approval for an equivalent intrathecal solution.
Use a different concentration, container or pump presentation if permitted by FDA requirements.
Challenge any unexpired Orange Book-listed patents through Paragraph IV certification.
Develop a differentiated omega-conopeptide outside MVIIA while relying on new composition and use patents.

The most defensible strategy would generally combine a non-infringing manufacturing process with a product-specific regulatory plan and a review of later formulation, dosing and device patents.

Key Takeaways

US 5,859,186 covers analgesia methods using pharmacologically defined omega conopeptides.
Claim 1 is functional and requires both guinea pig ileum inhibition and selective MVIIA-site binding.
Claim 2 adds a comparative MVIIA-to-site-2 binding selectivity ratio.
Claim 3 expressly identifies TVIA, MVIIA, SNX-236, SNX-159, SNX-239 and SNX-199, plus derivatives.
Claims 4 and 5 narrow the use to chronic pain and neuropathic pain.
MVIIA/SNX-111 is ziconotide, the active ingredient in Prialt.
The patent issued January 12, 1999, and expired in January 2016.
It no longer creates a live Paragraph IV or freedom-to-operate barrier.
Current commercial risk must be assessed through later patents, formulation rights, device rights, manufacturing patents and FDA requirements.
Ziconotide presents generic-entry challenges related to synthetic peptide quality and intrathecal administration rather than biosimilar interchangeability.

FAQs

Is US 5,859,186 still enforceable against a ziconotide manufacturer?

No. Its nominal US patent term ended in January 2016.

Does US 5,859,186 claim ziconotide itself?

No. Claim 3 identifies MVIIA/SNX-111, but the patent claims methods of producing analgesia rather than a standalone composition claim.

Does the patent require intrathecal administration?

No. The provided claims do not expressly require an intrathecal route, although intrathecal use is central to commercial ziconotide therapy.

Can a non-MVIIA omega-conopeptide infringe claim 1?

Potentially, if it is an omega conopeptide and satisfies the claimed guinea pig ileum and MVIIA-site binding activity ranges.

Is a ziconotide generic a biosimilar?

No. Ziconotide is a synthetic peptide product. A follow-on product would more likely proceed through a generic or other abbreviated drug-approval pathway rather than the conventional biologic biosimilar pathway.

References

U.S. Patent No. 5,859,186. (1999). Methods of producing analgesia using omega conopeptides. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2023). Prialt (ziconotide acetate) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources. USPTO.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	165977	⤷ Start Trial
Australia	3428093	⤷ Start Trial
Australia	689438	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,859,186

Summary for Patent: 5,859,186